Padagis Israel Pharmaceuticals Ltd. et al. vs. Bausch Health Ireland Limited et al.

Explore the PTAB proceeding IPR2023-01114 filed by Padagis Israel Pharmaceuticals Ltd. et al. on 2023-06-21. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-01114

Filing Date

2023-06-21

Accorded Filing Date

2023-06-21

Institution Decision Date

2024-01-12

Last Modified Date

2024-04-05

Proceeding Type

IPR

Termination Date

2024-01-12

Trial Status

Institution Denied

Parties & Counsel

Petitioner

Padagis Israel Pharmaceuticals Ltd. et al.

Represented By

Pitzel Cruz, Carolet al

Patent Owner / Respondent

Bausch Health Ireland Limited et al.

Represented By

Weisbruch, Aprilet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 16179561

Respondent Patent Number 11311482

External Links

Espacenet

Google Patents

Respondent Inventor Arturo Angel et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

9 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Bausch Health / Kilpatrick Townsend & Stockton LLP - Mailstop: IP Docketing - 22

Customer Number 112120

Address 1100 Peachtree Street, Suite 2800, Atlanta, GA, 30309, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
29476	John Pratt	404-815-6500
31661	Thomas Savitsky	908-927-0903
37330	Eugenia Garrett-Wackowski	925-472-5000
39381	Joseph Snyder	415-472-5000
45865	Vaibhav Kadaba	404-815-6500
52145	David Raczkowski	415-576-0200
55246	Joe Hao	301-230-9048
66184	Kenneth Shurtz	650-326-2400
66777	Thomas Walls	908-541-1297

Proceeding Documents

Notice: refund approved NOTICE

2024-04-05 FILING PARTY: BOARD

Download

Petitioner's Request for Refund of Post-Institution Fees OTHER

2024-03-29 FILING PARTY: PETITIONER

Download

Institution Decision: Deny DECISION

2024-01-12 FILING PARTY: BOARD

Download

Patent Owner's Second Revised Mandatory Notices NOTICE

2023-12-15 FILING PARTY: PATENT OWNER

Download

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5 ORDER

2023-12-13 FILING PARTY: BOARD

Download

Padagis Israel Pharmaceuticals Ltd. et al. vs. Bausch Health Ireland Limited et al.

Proceeding Overview

Parties & Counsel

Petitioner

Padagis Israel Pharmaceuticals Ltd. et al.

Represented By

Patent Owner / Respondent

Bausch Health Ireland Limited et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

Petitioner's Request for Refund of Post-Institution Fees OTHER

Institution Decision: Deny DECISION

Patent Owner's Second Revised Mandatory Notices NOTICE

ORDER Conduct of the Proceeding 37 C.F.R. § 42.5 ORDER

Petitioners' Reply to Patent Owner's Corrected Preliminary Response OTHER

Patent Owner's Corrected Preliminary Response POPR

Ex. 3001 Exhibit

Decision Granting Patent Owner’s Unopposed Motions for Pro Hac Vice Admission of Thomas P. Steindler and Christopher M. Bruno ORDER

Declaration of Christopher M. Bruno in Support of Patent Owner's Motion for Admission Pro Hac Vice Exhibit

Declaration of Thomas P. Steindler in Support of Patent Owner's Motion for Admission Pro Hac Vice Exhibit

Patent Owner's Motion for Admission Pro Hac Vice of Thomas P. Steindler MOTION

Patent Owner's Motion for Admission Pro Hac Vice of Christopher M. Bruno MOTION

Patent Owner's Updated Exhibit List NOTICE

Stipulation, No. 22-4248 Exhibit

Opinion, No. 20-5426 Exhibit

Complaint, No. 22-4248 Exhibit

Patent Owner's Preliminary Response POPR

Joint Proposed Discovery Plan, No. 22-4248 Exhibit

Trial Transcript, No. 20-5426 Exhibit

Stipulation and Order on Pretrial Schedule and Discovery, No. 22-4248 Exhibit

Memorandum from Katherine K. Vidal, Under Sec’y of Com. for Intell. Prop. & Dir. of the USPTO to Members of the Pat. Trial & Appeal Bd. Exhibit

Padagis Opening Post Trial Brief, No. 20-5426 Exhibit

Padagis Proposed Findings of Fact and Conclusions of Law, No. 20-5426 Exhibit

Padagis Amended Invalidity Contentions, No. 22-4248 Exhibit

Padagis Answer to Complaint, Affirmative Defenses and Counterclaims, No. 22-4248 Exhibit

Notice of Abandonment of U.S. Patent Application No. 16/179,576 Exhibit

Plaintiffs’ Proposed Findings of Fact and Conclusions of Law, No. 20-5426 Exhibit

First Amended Complaint, No. 22-4248 Exhibit

Padagis Invalidity Contentions, No. 22-4248 Exhibit

U.S. Patent Assignment Reel 059759, Frame 0311-15 Exhibit

Letter from William P. Deni, Jr. to Hon. Madeline Cox Arleo, U.S.D.J., No 22-4248 Exhibit

Order Consolidating Cases, No. 22-4248 Exhibit

Waiver of the Service of Summons, No. 22-4248 Exhibit

Complaint, No. 23-3393 Exhibit

Opening Statement on Behalf of the Padagis Defendants, No. 20-5426 Exhibit

U.S. Pat. No. 11,679,116 Exhibit

Patent Owner's Revised Mandatory Notices NOTICE

Patent Owner's Revised Power of Attorney NOTICE

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE NOTICE

Notice : Power of Attorney NOTICE

Notice : Mandatory Notice NOTICE

Declaration of Dr. Robert Schwartz Exhibit

Topical Tazarotene in Acne Vulgaris: Treatment Approaches, CUTIS Exhibit

Prescribing Information for DIFFERIN® Lotion Exhibit

Eichenfield, Evidence-Based Recommendations for the Treatment of Acne Exhibit

Arazlo Webpage Exhibit

National Medical and Treatment Audit Diagnosis Allocation Fact Sheet Exhibit

Prosecution History of the ’482 patent Exhibit

U.S. Patent No. 11,311,482 Exhibit

Kircik, L., Tretinoin Microsphere Gel Pump 0.04% Versus Tazarotene Cream Exhibit

Ismail, Subchronic and Chronic Toxicity of Tazarotene Gel Exhibit

U.S. Patent Pub. No. US 2012/0129824 Exhibit

Prosecution History of U.S. Pat. App. No. 16/179,576, Part 2 Exhibit

ClinicalTrials.gov, “A Phase 2 Dosing Ranging, Evaluator-Blinded Study" Exhibit

Curriculum Vitae of Dr. Robert Schwartz Exhibit

Prescribing Information for FABIOR® Foam Exhibit

Declaration of James Booydegraaf Exhibit

WO 2012/087443 Exhibit

IQVIA Sales Data For 0.05% Tazarotene For The Indication Of Acne Vulgaris Exhibit

Kircik, L., Importance of Vehicles in Acne Therapy Exhibit

Dosik, Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Exhibit

U.S. Patent Pub. No. 2012/0328670 Exhibit

Prescribing Information for Tazorac® Cream Exhibit

International Patent Publication WO 2016/205001 Exhibit